Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Ecnoglutide

Stage Phase 3Stale

Sponsor Hangzhou Sciwind Biosciences Co

Route oral and injection

Class GLP-1 RA

Mechanism GLP-1 analogue

Sources

registry, as of 2025-04-30Stale

https://clinicaltrials.gov/study/NCT05813795

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Hangzhou Sciwind Biosciences Co., Ltd.. Enrollment 664. Conditions Weight Management. The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity

ClinicalTrials.gov NCT05813795 protocol and results modules

registry, as of 2026-08-31Stale

https://clinicaltrials.gov/study/NCT07734311

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA). Overall status RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Sciwind Biosciences Co., Ltd.. Enrollment 360. Conditions Knee Osteoarthritis; Obesity. The main purpose of the study is to evaluate the efficacy and safety of ecnoglutide injections versus placebo in obese participants with KOA.

ClinicalTrials.gov NCT07734311 protocol and results modules

registry, as of 2026-09-23Stale

https://clinicaltrials.gov/study/NCT07836270

A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Hangzhou Sciwind Biosciences Co., Ltd.. Enrollment 192. Conditions Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities. The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents

ClinicalTrials.gov NCT07836270 protocol and results modules

registry, as of 2026-09-16Stale

https://clinicaltrials.gov/study/NCT07243171

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity. Overall status RECRUITING. Phases PHASE1,PHASE2. Lead sponsor Hangzhou Sciwind Biosciences Co., Ltd.. Enrollment 126. Conditions Overweight and/or Obesity; Weight Management. The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity

ClinicalTrials.gov NCT07243171 protocol and results modules

registry, as of 2025-09-10Stale

https://clinicaltrials.gov/study/NCT05184322

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults. Overall status COMPLETED. Phases PHASE1. Lead sponsor Sciwind Biosciences APAC CO Pty. Ltd.. Enrollment 87. Conditions Obesity; Type 2 Diabetes Mellitus. XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.

ClinicalTrials.gov NCT05184322 protocol and results modules

publication, as of 2026-08-07Stale

https://pubmed.ncbi.nlm.nih.gov/42310888/

Effect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants. Evaluate ecnoglutide (XW003) effects on rosuvastatin and digoxin pharmacokinetics (PKs) in healthy adu

PMID 42310888

Studies

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

Registry NCT05813795

Phase Phase 3

Status Completed

Enrollment 664

Start 2023-04-05

Primary completion 2024-06-20

Study completion 2024-10-10

C1- XW003 Low Dosage

Regimen once weekly

Comparator placebo

Population Weight Management

C1-Placebo

Regimen once weekly

Population Weight Management

C2- XW003 Medium Dosage

Regimen once weekly

Comparator placebo

Population Weight Management

C2-Placebo

Regimen once weekly

Population Weight Management

C3- XW003 High Dosage

Regimen once weekly

Comparator placebo

Population Weight Management

C3-Placebo

Regimen once weekly

Population Weight Management

A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)

Registry NCT07734311

Phase Phase 3

Status Recruiting

Enrollment 360

Start 2026-08-03

Primary completion 2028-05-31

Study completion 2028-06-30

Catalyst Primary completion. 2028-05-31. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Ecnoglutide Injection

Regimen once weekly

Comparator placebo

Population Knee Osteoarthritis; Obesity

Placebo

Regimen once weekly

Population Knee Osteoarthritis; Obesity

A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents

Registry NCT07836270

Phase Phase 3

Status Not yet recruiting

Enrollment 192

Start 2026-10-31

Primary completion 2028-06-08

Study completion 2028-09-30

Catalyst Primary completion. 2028-06-08. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Ecnoglutide Injection Dose 1

Regimen once weekly

Comparator placebo

Population Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities

Ecnoglutide Injection Dose 2

Regimen once weekly

Comparator placebo

Population Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities

Ecnoglutide Injection Dose 3

Regimen once weekly

Comparator placebo

Population Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities

placebo

Regimen once weekly

Population Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities

A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Registry NCT07243171

Phase Phase 1/2

Status Recruiting

Enrollment 126

Start 2025-11-18

Primary completion 2027-01-05

Study completion 2027-04-28

Catalyst Primary completion. 2027-01-05. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

oral ecnoglutide dose 1

Regimen once daily

Comparator placebo

Population Overweight and/or Obesity; Weight Management

oral ecnoglutide dose 2

Regimen once daily

Comparator placebo

Population Overweight and/or Obesity; Weight Management

oral ecnoglutide dose 3

Regimen once weekly

Comparator placebo

Population Overweight and/or Obesity; Weight Management

oral ecnoglutide dose 4

Regimen once weekly

Comparator placebo

Population Overweight and/or Obesity; Weight Management

placebo dose 1

Regimen once daily

Population Overweight and/or Obesity; Weight Management

placebo dose 2

Regimen once weekly

Population Overweight and/or Obesity; Weight Management

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Registry NCT05184322

Phase Phase 1

Status Completed

Enrollment 87

Start 2022-04-12

Primary completion 2024-07-13

Study completion 2025-03-25

Cohort 1A/1B

Regimen once weekly

Weeks 6

Population Obesity; Type 2 Diabetes Mellitus

Cohort 2

Regimen once weekly

Weeks 6

Population Obesity; Type 2 Diabetes Mellitus

Cohort 3

Regimen once weekly

Weeks 6

Population Obesity; Type 2 Diabetes Mellitus

Cohort 4

Regimen once weekly

Weeks 6

Population Obesity; Type 2 Diabetes Mellitus

Cohort 5

Regimen once weekly

Weeks 6

Population Obesity; Type 2 Diabetes Mellitus

Cohort 6

Regimen once weekly

Weeks 6

Population Obesity; Type 2 Diabetes Mellitus